Apr 8, 2024 | LIPIDS
2) Not all pts w/ #hyperlipidemia & associated #CV risk can tolerate #statins, & others are statin-refractory. Much research on non-statin alternatives. @DrMarthaGulati, #cardiologist @CedarsSinai is a leader in this space & is President of...
Nov 8, 2023 | LIPIDS
2) This program is supported by an educational grant from Esperion Therapeutics & is intended for #HCPs. Statement of accreditation & faculty disclosures at https://t.co/gvXca4G9Xm. Earn .75hr 🆓CE/#CME by following this 🧵!@MedTweetorials— cardio-met...
Sep 22, 2023 | LIPIDS
1b) @lipiddoc is a #lipidologist🩺🧬@nyulangone @NYUCVDPrevent. He is President of the Foundation of @nationallipid, Past-President of both @nationallipid AND @LipidBoard, and is Director of @BHLipidClinic. @cardiomet_CE is proud to welcome @lipiddoc as new...
Sep 19, 2023 | LIPIDS
2) This presentation was originally delivered by @NP_ltl_a at an accredited satellite symposium at @nationallipid's June 2023 congress. She shared the podium there with lipidology & #preventive #cardiology experts @alanbrownmd, @jpenamd, &...
Aug 25, 2023 | LIPIDS
1b) @ProfKausikRay will particularly focus on data for non-#statin #LLT from #ESCCongress, following on the heels of the presentation of the primary analysis of #CLEAR_Outcomes at #ACC23, about which you learned from @CMichaelGibson in our tweetorial at...
Jun 26, 2023 | LIPIDS
1b) Patients with #diabetes are at substantially increased risk of #CV disease, often in association with hyperlipidemia #HL. Therefore it's no surprise that a 🌶️topic at #ADA2023 would be management of #HL and #CV disease prevention!#FOAMed @MedTweetorials—...